Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Receptor Subtype-Dependent Positive and Negative Modulation of GABAA Receptor Function by Niflumic Acid, a Nonsteroidal Anti-Inflammatory Drug

Saku T. Sinkkonen, Salla Mansikkamäki, Tommi Möykkynen, Hartmut Lüddens, Mikko Uusi-Oukari and Esa R. Korpi
Molecular Pharmacology September 2003, 64 (3) 753-763; DOI: https://doi.org/10.1124/mol.64.3.753
Saku T. Sinkkonen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salla Mansikkamäki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tommi Möykkynen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hartmut Lüddens
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikko Uusi-Oukari
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esa R. Korpi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In addition to blocking cyclooxygenases, members of the fenamate group of nonsteroidal anti-inflammatory drugs have been proposed to affect brain GABAA receptors. Using quantitative autoradiography with GABAA receptor-associated ionophore ligand [35S]t-butylbicyclophosphorothionate (TBPS) on rat brain sections, one of the fenamates, niflumate, at micromolar concentration was found to potentiate GABA actions in most brain areas, whereas being in the cerebellar granule cell layer an efficient antagonist similar to furosemide. With recombinant GABAA receptors expressed in Xenopus laevis oocytes, we found that niflumate potentiated 3 μM GABA responses up to 160% and shifted the GABA concentration-response curve to the left in α1β2γ2 receptors, the predominant GABAA receptor subtype in the brain. This effect needed the γ2 subunit, because on α1β2 receptors, niflumate exhibited solely an antagonistic effect at high concentrations. The potentiation was not abolished by the specific benzodiazepine site antagonist flumazenil. Niflumate acted as a potent antagonist of α6β2 receptors (with or without γ2 subunit) and of αXβ2γ2 receptors containing a chimeric α1 to α6 subunit, which suggests that niflumate antagonism is dependent on the same transmembrane domain 1- and 2-including fragment of the α6 subunit as furosemide antagonism. This antagonism was noncompetitive because the maximal GABA response, but not the potency, was reduced by niflumate. These data show receptor subtype-dependent positive and negative modulatory actions of niflumate on GABAA receptors at clinically relevant concentrations, and they suggest the existence of a novel positive modulatory site on α1β2γ2 receptors that is dependent on the γ2 subunit but not associated with the benzodiazepine binding site.

  • Received January 14, 2003.
  • Accepted June 11, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 64 (3)
Molecular Pharmacology
Vol. 64, Issue 3
1 Sep 2003
  • Table of Contents
  • About the Cover
  • Index by author
  • [Supplemental Data]
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Receptor Subtype-Dependent Positive and Negative Modulation of GABAA Receptor Function by Niflumic Acid, a Nonsteroidal Anti-Inflammatory Drug
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Receptor Subtype-Dependent Positive and Negative Modulation of GABAA Receptor Function by Niflumic Acid, a Nonsteroidal Anti-Inflammatory Drug

Saku T. Sinkkonen, Salla Mansikkamäki, Tommi Möykkynen, Hartmut Lüddens, Mikko Uusi-Oukari and Esa R. Korpi
Molecular Pharmacology September 1, 2003, 64 (3) 753-763; DOI: https://doi.org/10.1124/mol.64.3.753

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Receptor Subtype-Dependent Positive and Negative Modulation of GABAA Receptor Function by Niflumic Acid, a Nonsteroidal Anti-Inflammatory Drug

Saku T. Sinkkonen, Salla Mansikkamäki, Tommi Möykkynen, Hartmut Lüddens, Mikko Uusi-Oukari and Esa R. Korpi
Molecular Pharmacology September 1, 2003, 64 (3) 753-763; DOI: https://doi.org/10.1124/mol.64.3.753
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cysteine151 in Keap1 Drives CDDO-Me Pharmacodynamic Action
  • Allosteric Modulation of Metabotropic Glutamate Receptor 1
  • Mechanism of Selective Action of Paraherquamide A
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics